TY - JOUR T1 - Neoadjuvant Docetaxel/Cyclophosphamide in Triple-negative Breast Cancer: Predictive Value of Class III-β Tubulin and Non-basal Subtype JF - Anticancer Research JO - Anticancer Res SP - 907 LP - 912 VL - 35 IS - 2 AU - KAZUHIRO SHIMADA AU - TAKASHI ISHIKAWA AU - KUMIKO KITA AU - KAZUTAKA NARUI AU - SADAYOSHI SUGAE AU - DAISUKE SHIMIZU AU - MIKIKO TANABE AU - TAKESHI SASAKI AU - TAKASHI CHISHIMA AU - YASUSHI ICHIKAWA AU - ITARU ENDO Y1 - 2015/02/01 UR - http://ar.iiarjournals.org/content/35/2/907.abstract N2 - Aim: We aimed to clarify which breast cancer subtypes respond best to docetaxel/cyclophosphamide chemotherapy (TC) as neoadjuvant chemotherapy (NAC). Patients and Methods: We analyzed pathological responses, clinicopathological characteristics and biological markers (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, p53, topoisomerase IIα, class III β tubulin, cytokeratin 5/6, epidermal growth factor receptor (EGFR)) in specimens from 79 patients who received NAC-TC. Results: Out of 79 patients, 33 (41.8%) achieved quasipathological complete responses (QpCR). Univariate analysis associated negative ER (p<0.001), negative PR (p=0.007), triple-negative subtype (TNBC; p=0.001), high Ki-67 (p=0.022) and low class III β tubulin (p=0.032) with QpCR. Multivariate analyses associated only negative ER (p=0.050) and low class III β tubulin (p=0.028) and only non-basal subtype in TNBC with QpCR. Conclusion: NAC-TC may be especially effective in ER–breast cancer with low class III β tubulin or non-basal TNBC. ER -